ClinicalTrials.gg
CompletedNCT03655678Updated Dec 17, 2025

A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia

A Phase 2/3 interventional study of CTX001 in Beta-Thalassemia, Thalassemia and Genetic Diseases, Inborn, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 14 sites in 5 countries. Open to participants aged 12 Years to 35 Years. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
59
Allocation
Not applicable
Ages
12 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in beta-Thalassemia with a site in United States — 22 open to participants now, 36 under way, 8 of them phase 3. beta-Thalassemia · United States.

Enrollment
18th of 71
59 · median 25
Started
2018
with 5 others
Phase 2/3
Only one
of the 91
Registered
56th of 91
by date
Lead sponsor
4 of 91
Vertex Pharmaceuticals Incorporated

Among the 91 studies in beta-Thalassemia with a site in United States, this one is the 18th largest by enrollment of the 71 interventional ones that give a count, is one of 6 that started in 2018, is the only one in phase 2/3, and was the 56th registered.

beta-Thalassemia

294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.

Browse beta-Thalassemia studies →

Open to participants now

22 of the 91 studies in beta-Thalassemia with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 12 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in beta-Thalassemia with a site in United States, or all of them as a file.
02

Study summary

This is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in participans with transfusion-dependent β-thalassemia (TDT). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) using CTX001.

03

Conditions studied

  • Beta-Thalassemia
  • Thalassemia
  • Genetic Diseases, Inborn
  • Hematologic Diseases
  • Hemoglobinopathies

Keywords

  • CRISPR-Cas9
  • Beta-Thalassemia
  • Hemoglobinopathies
04

Who can participate

Ages eligible
12 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of transfusion-dependent β-thalassemia (TDT) as defined by

    1. Documented homozygous β-thalassemia or compound heterozygous β-thalassemia including β-thalassemia/ E (HbE). Participants can be enrolled based on historical data, but a confirmation of the genotype using the study central laboratory will be required before busulfan conditioning
    2. History of at least 100 mL/kg/year or ≥10 units/year of packed RBC transfusions in the prior 2 years before signing the consent or the last rescreening for patients going through re-screening
  • Eligible for stem cell transplant as per investigator's judgment

Key Exclusion Criteria:

  • A willing and healthy 10/10 Human Leukocyte Antigen (HLA)-matched related donor is available per investigator's judgement
  • Prior allo-HSCT
  • Participants with associated α-thalassemia and >1 alpha deletion or alpha multiplications
  • Participants with sickle cell beta thalassemia variant
  • and active bacterial, viral, fungal, or parasitic infection as determined by the investigator
  • White blood cell (WBC) count \<3 × 10\^9/L or count \<50 × 10\^9/L not related to hypersplenism

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    CTX001

    CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Participants will receive a single infusion of CTX001 through a central venous catheter.

    Biological: CTX001

Interventions

  • BiologicalCTX001

    Administered by IV infusion following myeloablative conditioning with busulfan

    Also known as: Exagamglogene autotemcel, Exa-cel

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving transfusion independence for at least 12 consecutive months (TI12)

    Time frame: From 60 days after last RBC transfusion up to 24 months post-CTX001 infusion]

  2. Proportion of participants with engraftment (first day of 3 consecutive measurements of absolute neutrophil count [ANC] ≥500/µL on three different days)

    Time frame: Within 42 days after CTX001 infusion

  3. Time to neutrophil and platelet engraftment

    Time frame: Days post-infusion to engraftment

  4. Frequency and severity of collected adverse events (AEs)

    Time frame: Signing of informed consent through Month 24 visit

  5. Incidence of transplant-related mortality (TRM)

    Time frame: Baseline (pre-transfusion) to 100 days and 1 year post-CTX001 infusion

  6. All-cause mortality

    Time frame: Signing of informed consent through Month 24 visit

Secondary outcomes

  1. Proportion of participants achieving transfusion independence for at least 6 consecutive months (TI6)

    Time frame: From 60 days after last RBC transfusion up to 24 months post-CTX001 infusion

  2. Proportion of participants achieving at least 95 percent (%), 90%, 85%, 75%, and 50% reduction from baseline in annualized volume of RBC transfusions after Month 10 after CTX001 infusion

    Time frame: From Month 10 up to 24 months post-CTX001 infusion

  3. Relative reduction from baseline in annualized volume of RBC transfusions after Month 10 after CTX001 infusion

    Time frame: From Month 10 up to 24 months post-CTX001 infusion

  4. Duration of transfusion free in participants who have achieved TI12

    Time frame: From 60 days after last RBC transfusion up to 24 months post-CTX001 infusion

  5. Proportion of alleles with intended genetic modification in peripheral blood leukocytes over time

    Time frame: Day 1 CTX001 infusion through Month 24 visit

  6. Proportion of alleles with intended genetic modification present in CD34+ cells of bone marrow over time

    Time frame: Day 1 CTX001 infusion through Month 24 visit

  7. Change in fetal hemoglobin concentration over time

    Time frame: Baseline (pre-transfusion) through Month 24 visit

  8. Change in total hemoglobin concentration over time

    Time frame: Baseline (pre-transfusion) through Month 24 visit

  9. Change in health-related quality of life (HRQoL) from baseline over time using EuroQol Questionnaire (5 dimensions - 5 levels of severity - EQ-5D-5L)

    The EQ-5D-5L Questionnaire consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The EQ-5D comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and 5 levels: no problems to extreme problems. The subject marks the most appropriate statement in each dimension, resulting in a 1-digit number for that dimension. The digits can be combined in a 5-digit number describing the subject's health state. The EQ VAS records the subject's self-rated health on a 100-point VAS, endpoints labelled "the best health you can imagine" and "the worst health you can imagine."

    Time frame: Screening visit through Month 24 visit

  10. Change in health-related quality of life (HRQoL) from baseline over time using the Functional assessment of cancer therapy-bone marrow transplant questionnaire (FACT-BMT)

    The FACT-BMT Questionnaire includes physical, social, family, emotional, and functional well-being, and treatment specific concerns of bone marrow transplantation. Each statement has a 5-point Likert-type response scale ranging from 0=not at all to 4=very much. The subject marks one number per line as it applies to the past 7 days. Questionnaires are scored; the higher the score, the better the QOL.

    Time frame: Screening visit through Month 24 visit

  11. Change in patient reported outcome (PRO) over time assessed using EQ-5D-Youth (EQ-5D-Y)

    Time frame: Screening visit through Month 24 visit

  12. Change in PRO over time assessed using pediatric quality of life inventory (PedsQL)

    Time frame: Screening visit through Month 24 visit

  13. Changes in liver iron concentration (LIC) and cardiac iron content (CIC) and ferritin parameters of iron overload

    Time frame: Screening visit through Month 24 visit

  14. Proportion of participants receiving iron chelation therapy

    Time frame: 1 month post-CTX001 infusion through Month 24 visit

07

Study locations

14 sites
  • Lucile Packard Children's Hospital
    Palo Alto, California 94304, United States
  • Ann & Robert Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Columbia University Medical Center (21+ years)
    New York, New York 10032, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • The Children's Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood Cancers
    Nashville, Tennessee 37203, United States
  • The Hospital for Sick Children
    Toronto, Canada
  • British Columbia Children's Hospital
    Vancouver, Canada
  • Universitätsklinikum Düsseldorf Hospital Duesseldorf
    Düsseldorf, Germany
  • Regensburg University Hospital, Clinic and Polyclinic for Paediatric and Adolescent Medicine
    Regensburg, Germany
  • University Hospital Tübingen
    Tübingen, Germany
  • Ospedale Pediatrico Bambino Gesù, IRCCS
    Rome, Italy
  • Imperial College Healthcare NHS Trust, Hammersmith Hospital
    London, United Kingdom
  • University College London Hospitals NHS Foundation Trust
    London, United Kingdom
08

References and documents

Publications

  • Sheth S, Corbacioglu S, de la Fuente J, Algeri M, Rupprecht J, Kuo KHM, Shah AJ, Lang P, Merkeley H, Carpenter B, Mapara MY, Liem RI, Grupp S, Chopra Y, Li AM, Kwiatkowski JL, Kirby-Allen M, Cappellini MD, Kattamis A, Zairis S, Liu T, Hobbs W, Frangoul H, Locatelli F, Meisel R; CLIMB THAL-111 and CLIMB-131 Study Groups. Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion-Dependent beta-Thalassemia. Am J Hematol. 2026 Aug;101(8):1969-1979. doi: 10.1002/ajh.70382. Epub 2026 Jun 7. PubMed 42252696 ↗
  • Fuente J, Frangoul H, Lang P, Wall D, Meisel R, Corbacioglu S, Li AM, Shah AJ, Carpenter B, Kwiatkowski JL, Mapara MY, Liem RI, Rupprecht J, Kuo KHM, Merkeley H, Algeri M, Smith W, Kohli P, Li N, Rubin J, Zhang S, Hobbs W, Locatelli F. Improvements in health-related quality of life in patients with transfusion-dependent beta-thalassemia after exagamglogene autotemcel. Blood Adv. 2025 Dec 23;9(24):6502-6510. doi: 10.1182/bloodadvances.2025016702. PubMed 40862696 ↗
  • Locatelli F, Lang P, Wall D, Meisel R, Corbacioglu S, Li AM, de la Fuente J, Shah AJ, Carpenter B, Kwiatkowski JL, Mapara M, Liem RI, Cappellini MD, Algeri M, Kattamis A, Sheth S, Grupp S, Handgretinger R, Kohli P, Shi D, Ross L, Bobruff Y, Simard C, Zhang L, Morrow PK, Hobbs WE, Frangoul H; CLIMB THAL-111 Study Group. Exagamglogene Autotemcel for Transfusion-Dependent beta-Thalassemia. N Engl J Med. 2024 May 9;390(18):1663-1676. doi: 10.1056/NEJMoa2309673. Epub 2024 Apr 24. PubMed 38657265 ↗
  • Brusson M, Miccio A. Genome editing approaches to beta-hemoglobinopathies. Prog Mol Biol Transl Sci. 2021;182:153-183. doi: 10.1016/bs.pmbts.2021.01.025. Epub 2021 Mar 1. PubMed 34175041 ↗
  • Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BK, Foell J, de la Fuente J, Grupp S, Handgretinger R, Ho TW, Kattamis A, Kernytsky A, Lekstrom-Himes J, Li AM, Locatelli F, Mapara MY, de Montalembert M, Rondelli D, Sharma A, Sheth S, Soni S, Steinberg MH, Wall D, Yen A, Corbacioglu S. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia. N Engl J Med. 2021 Jan 21;384(3):252-260. doi: 10.1056/NEJMoa2031054. Epub 2020 Dec 5. PubMed 33283989 ↗

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Nov 2025, 85 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2018
First posted
Aug 31, 2018
StartActual
Sep 14, 2018
Primary completionActual
Nov 13, 2025
CompletionActual
Nov 13, 2025
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03655678
Collaborators
CRISPR Therapeutics
Responsible party
Sponsor
First posted
Aug 31, 2018
Start date
Sep 14, 2018
Primary completion
Nov 13, 2025
Completion
Nov 13, 2025
Last update
Dec 17, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Exagamglogene autotemcel

Start the discussion